TWINNING ON DNA-BASED CANCER VACCINES
(VACTRAIN)
Date du début: 1 janv. 2016,
Date de fin: 31 déc. 2018
PROJET
TERMINÉ
The objective of this Twinning project is to significantly strengthen the research in Riga Stradins University (RSU; Latvia) in the smart specialization area of Latvia “bio-medicine, medical technologies, and biotechnologies” with application to immunotherapy of cancer through building an up-rising connections with two internationally leading research institutions, Institute of Microbiology, Tumor and Cell Biology, Karolinska Institutet (Sweden) and the Department of General Biophysics, University of Lodz (Poland). Both represent centers of excellence in the design, testing and clinical applications of a wide class of immunotherapeuticals, with focus on technologies exploiting naked nucleic acids.
Accédez au prémier réseau pour la cooperation européenne
Se connecter
ou
Créer un compte
Pour accéder à toutes les informations disponibles
Coordinateur
RIGAS STRADINA UNIVERSITATE
€ 357 575,00- Dzirciema street 16 1007 RIGA (Latvia)
Details
- 100% € 999 475,00
-
H2020-EU.4.b.
- Projet sur CORDIS platform
3 Participants partenaires
KAROLINSKA INSTITUTET
€ 327 295,00- Nobels Vag 5 17177 STOCKHOLM (Sweden)
UNIWERSYTET LODZKI
€ 165 855,00- UL PREZYDENTA GABRIELA NARUTOWICZA 68 90 136 LODZ (Poland)
R.E KAVETSKY INSTITUTE OF EXPERIMENTAL PATHOLOGY ONCOLOGY AND RADIOBIOLOGY OF NATIONAL ACADEMY OF SCIENCES OF UKRAINE
€ 148 750,00- VASYLKIVSKA STR 45 03022 KYIV (Ukraine)